Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights
Amarin Corporation plc (NASDAQ:AMRN) is one of the best performing pharma stocks in 2025.
Amarin Corp Plc (AMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Sarissa Capital Management Alex Denner | 1,673,395 | $23,352,227 | +35% | 10.48% |
| 2. | Kynam Capital Derrick Tang | 389,273 | $5,432,305 | -33% | 0.35% |
| 3. | Eversept Partners Kamran Moghtaderi | 172,188 | $2,402,884 | +3% | 0.12% |
| 4. | Citadel Investment Group Ken Griffin | 168,004 | $2,344,496 | +38% | 0% |
| 5. | Millennium Management Israel Englander | 166,235 | $2,319,809 | +26% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.64 | 160,000 | $102,400.00 | 805,380 | 2024-08-02 | Filing | |
| $1.09 | 14,426 | $15,724.34 | 314,426 | 2024-01-22 | Filing | |
| $1.06 | 67,222 | $71,255.32 | 300,000 | 2023-08-16 | Filing | |
| $1.06 | 25,845 | $27,266.48 | 233,778 | 2023-08-16 | Filing | |
| $1.05 | 12,700 | $13,335.00 | 206,933 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.79 | 34,131 | $26,963.49 | 566,100 | 2023-12-12 | Filing | |
| $5.25 | 120,000 | $630,240.00 | 205,010 | 2021-08-12 | Filing | |
| $8.03 | 25,370 | $203,670.36 | 382,996 | 2021-02-01 | Filing | |
| $8.06 | 192,358 | $1,550,463.19 | 408,366 | 2021-02-01 | Filing | |
| $8.01 | 143,392 | $1,149,258.20 | 388,112 | 2021-01-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 330,109 | $4,606,671 | 0% | |
| 2. | 142,540 | $2,265,673 | 0.43% | |
| 3. | 111,168 | $1,551,349 | 0% | |
| 4. | 104,345 | $1,456,134 | 0% | |
| 5. | 100,000 | $1,395,500 | 1.14% |
News See All
10 Best Performing Pharma Stocks in 2025
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...
Amarin Corporation plc (NASDAQ:AMRN) Q3 2025 Earnings Call Transcript
Operator: Welcome to Amarin Corporation's conference call to discuss its third quarter 2025 financial results.
Amarin Corporation plc (NASDAQ:AMRN) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Amarin Corporation's Conference Call to discuss its Second Quarter 2025 Financial Results. I would now like to turn the conference over to Mr.
Amarin Corporation plc (NASDAQ:AMRN) Q1 2025 Earnings Call Transcript
Operator: Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results.
Amarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call Transcript
Operator: Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2024 Business Update and Financial Results.
Amarin Corporation plc (NASDAQ:AMRN) Q3 2024 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN) Q3 2024 Earnings Call Transcript October 30, 2024Amarin Corporation plc reports earnings inline with expectations.
Amarin Corporation plc (NASDAQ:AMRN) Q2 2024 Earnings Call Transcript
Operator: Welcome to Amarin Corporation’s Conference Call to discuss its Second Quarter 2024 Business Update and Financial Results.
Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript
Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.01 EPS, expectations were $-0.0075.
Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript
Amarin Corporation plc beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.04.
Hedge Fund Resource Center Billionaire Hedge Funds
